Dose effect of influenza vaccine on protection against laboratory-confirmed influenza illness among children aged 6 months to 8 years of age in southern China, 2013/14–2015/16 seasons: a matched case–control study. Issue 3 (3rd March 2020)

• Record Type: Journal Article
• Authors: Fu, Chuanxi; Greene, Carolyn M.; He, Qing; Liao, Ying; Wan, Yanmin; Shen, Jichuan; Rong, Chao; Zhou, Suizan
• Is Part Of: Human vaccines & immunotherapeutics. Volume 16:Issue 3(2020)
• Page Start: 595
• Page End: 601
• Publication Date: 2020-03-03
• Subjects: Influenza -- vaccine effectiveness -- dose effect; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2019.1662267
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Background We conducted a matched case–control study in China during the 2013/14–2015/16 influenza seasons to estimate influenza vaccine effectiveness (VE) by dose among children aged 6 months to 8 years. Methods Cases were laboratory-confirmed influenza infections identified through the influenza-like illness sentinel surveillance network in Guangzhou. Age- and sex-matched community controls were randomly selected through the expanded immunization program database. We defined priming as receipt of ≥1 dose of influenza vaccine during the immediate prior season. Results In total, 4, 185 case–control pairs were analyzed. Among children 6–35 months, VE for current season dose(s) across the three seasons during 2013/14–2015/16 were 59% (95% Confidence Interval: 44–71%), 12% (−11%, 30%), 54% (32–69%); among unprimed children 6–35 months, VE for 1 vs 2 current season doses were 45% (8–67%) vs 65% (46–78%), −2% (−53%, 32%) vs 19% (−11%, 40%), and 37% (−24%, 68%) vs 61% (32–78%). Among children aged 3–8 years, VE for current season dose(s) across study seasons were 62% (36–78%), 43% (22–58%), 32% (1–53%). VE for unprimed children receiving 1 dose only in current season was insignificant or lower than among all children. Conclusion Findings support utility of providing second dose ("booster dose") of seasonal influenza vaccine to unprimed children aged 6–35 months, and the need to study further dose effect of a booster dose among unprimed children aged 3–8 years in China.